



Cite this: *Med. Chem. Commun.*,
2019, 10, 1231

Methicillin-resistant *Staphylococcus aureus* (MRSA): antibiotic-resistance and the biofilm phenotype

Kelly M. Craft,  Johny M. Nguyen, Lawrence J. Berg and Steven D. Townsend *

Staphylococcus aureus (*S. aureus*) is an asymptomatic colonizer of 30% of all human beings. While generally benign, antibiotic resistance contributes to the success of *S. aureus* as a human pathogen. Resistance is rapidly evolved through a wide portfolio of mechanisms including horizontal gene transfer and chromosomal mutation. In addition to traditional resistance mechanisms, a special feature of *S. aureus* pathogenesis is its ability to survive on both biotic and abiotic surfaces in the biofilm state. Due to this characteristic, *S. aureus* is a leading cause of human infection. Methicillin-resistant *S. aureus* (MRSA) in particular has emerged as a widespread cause of both community- and hospital-acquired infections. Currently, MRSA is responsible for 10-fold more infections than all multi-drug resistant (MDR) Gram-negative pathogens combined. Recently, MRSA was classified by the World Health Organization (WHO) as one of twelve priority pathogens that threaten human health. In this targeted mini-review, we discuss MRSA biofilm production, the relationship of biofilm production to antibiotic resistance, and front-line techniques to defeat the biofilm-resistance system.

Received 26th January 2019,
Accepted 12th March 2019

DOI: 10.1039/c9md00044e

rsc.li/medchemcomm

I. Introduction

Nosocomial infections are a major global health concern.^{1–7} While significant progress has been made preventing transmission, on any given day, approximately 5% of patients in developed countries and 10% of patients in developing countries will acquire a hospital-associated infection (HAI).^{8–11} Higher rates of HAI are seen in developing countries due to limited resources.^{12,13} Furthermore, HAI rates can rise to around 50% for patients in intensive care units (ICUs).¹⁴

Staphylococcus aureus (*S. aureus*) is a common cause of nosocomial infection.^{15–17} *S. aureus* is a Gram-positive commensal that persistently colonizes the skin and mucosae of approximately 30% of the human population.¹⁸ Another 60% of people are transiently colonized.¹⁹ While the nose is the most frequent carriage site, the skin, axillae, perineum, and pharynx are also common sites of colonization.²⁰

While *S. aureus* appears as an innocuous commensal, it is responsible for a major infectious disease burden.¹⁸ As an adaptable pathogen, *S. aureus* can cause a wide range of illnesses after an open wound or “entry point” is inoculated.²¹ For example, the most common type of staph infection in adults is the boil, a pocket of pus that develops in a hair follicle or an oil gland. In children, the most common infection

is impetigo, a highly contagious skin infection that appears as red sores on the face near the mouth and nose. Other clinical manifestations of staph infection include endocarditis, osteoarticular infection, pneumonia, toxic shock syndrome, and prosthetic device and catheter infections.²²

Staphylococcal infections occur when host defense mechanisms are low as a result of debilitating illness, open wounds, or treatment with steroids or other drugs that compromise immunity (Fig. 1). Indeed, *S. aureus* infection rates in ICUs are of particular concern, and the risk of infection increases with the duration of a patient's stay in these units.^{14,23,24} This characteristic of *Staphylococcal* infections is largely attributable to the fact that *S. aureus* is an opportunistic pathogen that possesses an extensive arsenal of virulence factors that enable the organism to take advantage of a compromised host.^{25,26} Moreover, a number of strains possess a battery of resistance mechanisms against conventional antibiotics.²⁷ To compound the problem, *S. aureus* can live in the biofilm state. Biofilms are organized populations of bacteria encapsulated in a self-produced extracellular polymeric matrix that adheres to biotic and abiotic surfaces.^{28,29} Importantly, biofilms provide protection from antibiotics and the host immune system. Additionally, bacteria in the biofilm state display increased resistance to stress compared to those in the planktonic state. Given the ability of biofilms to shield bacteria from harsh host environments, biofilm adds an additional level of complexity to the problem of antimicrobial resistance.

Department of Chemistry, Vanderbilt University, 7300 Stevenson Science Center, Nashville, TN, 37235, USA. E-mail: steven.d.townsend@vanderbilt.edu




Fig. 1 Scanning electron microscope (SEM) image of *Staphylococcus aureus*-infected bone (image courtesy of Dr. Jennifer Gaddy at Vanderbilt University).

II. Methicillin-resistant *S. aureus* (MRSA)

S. aureus is an adaptable organism with the ability to evolve resistance to an array of antibiotics. Resistance development and subsequent dissemination are consequences of horizontal gene transfer (HGT), *i.e.* the lateral movement of genetic information between organisms. Notably, HGT enables new, antibiotic-resistant variants to arise without the need for genetic mutation.^{30–32} This mode of action is often encountered in hospitals where selective pressure for resistance is enhanced. Inevitably, hospital-associated resistant strains enter and spread throughout the community.

Antibiotic resistance in *S. aureus* was first observed in the 1940s when infections caused by penicillin-resistant *S. aureus* (PRSA) emerged in hospitals.^{33,34} These strains produce a plasmid-encoded lactamase (penicillinase) capable of hydrolyzing the β -lactam ring of penicillin (1). As this ring is the antimicrobial warhead of penicillin, its hydrolysis renders the drug inactive (2) (Fig. 2A). Within a few years after its appearance in hospitals, PRSA had spread to the community. By the 1950s and 1960s, penicillin-resistant strains in the community had reached pandemic levels.³³ Today, more than 90% of *Staphylococcal* isolates produce penicillinase and are consequently resistant to penicillin.³⁵

In an attempt to combat penicillin resistance, methicillin (3) was introduced in 1959.^{33,34} Methicillin features a larger aryl moiety near the β -lactam ring which reduces its affinity for *Staphylococcal* β -lactamases.³⁶ Unfortunately, the first reports of methicillin resistance were observed in 1961, just 2 years after methicillin's introduction. Contrary to penicillin resistance, methicillin resistance is not a result of drug inactivation, *i.e.* hydrolysis of the β -lactam ring, but rather a result of drug target modification (Fig. 2B). Methicillin-resistant *S. aureus* (MRSA) strains express an additional penicillin-binding protein (PBP), known as PBP2a, which has been hypothesized to have originated from *Staphylococcus sciuri*.³⁶




Fig. 2 Mechanisms of *Staphylococcus aureus* resistance to penicillin (1), methicillin (3), and vancomycin (4). (A) Penicillin is inactivated by bacterial β -lactamases that hydrolyze the β -lactam ring, which forms an inactive penicilloic acid. (B) Resistance to methicillin, a modified-penicillin scaffold featuring a larger aryl side chain that is resistant to β -lactamase action, is driven by the expression of the alternative transpeptidase, PBP2a, which has a lower affinity for methicillin. Resistance to vancomycin results from modification of the terminal dipeptide of cell wall peptidoglycan chains, which reduces the affinity of the dipeptide for vancomycin.

PBPs are membrane-bound enzymes that catalyze the cross-linking or transpeptidation reactions that link peptidoglycan chains in the bacterial cell wall.³⁵ In the absence of resistance mechanisms, β -lactams inhibit the transpeptidase domain of PBPs. This results in inhibition of the cross-linking reactions which are integral to formation of a stable peptidoglycan layer. Without a structurally sound peptidoglycan layer, bacterial cell walls become weak and lack the ability to contain the cytoplasmic contents of the cell.³⁶ While PBP2a shares the structural features associated with penicillin binding that are common to other PBPs, PBP2a has a low affinity for all β -lactams. Indeed, the PBP2a active site is able to block the binding of β -lactams while simultaneously allowing cross-linking to proceed.³⁵ Importantly, while β -lactamase-mediated resistance is a narrow-spectrum mechanism, *i.e.* only penicillin is inactivated by the enzyme, methicillin resistance due to PBP2a expression is a broad-spectrum resistance mechanism. All β -lactams, including penicillins, cephalosporins, and carbapenems, are inactive against bacterial strains expressing PBP2a.

The inability of β -lactams to combat staph infections has led to an increased use of vancomycin (4) and the inevitable evolution of vancomycin-resistant *S. aureus* (VRSA) strains.³⁷ Similar to methicillin resistance, vancomycin resistant *S.*

aureus strains derive their resistance from structural modification of the target. Modification of the terminal dipeptide of cell wall peptidoglycan chains from D-alanyl-D-alanine (D-Ala-D-Ala) to D-alanyl-D-lactate (D-Ala-D-Lac) reduces the affinity of the dipeptide for vancomycin, thus preventing disruption of peptidoglycan cross-linking (Fig. 2B).³⁸

Today, MRSA is pandemic. The rise to pandemic status started with hospital-acquired MRSA clones in the 1960s. This then fostered community-acquired MRSA clones in the 1990s and finally livestock-associated MRSA clones in the 2000s. The evolution of MRSA from initial reports to widespread dissemination parallels the trajectory of PRSA in the 1940s. Unsurprisingly, MRSA is highly prevalent in hospitals (Fig. 3). The highest rates of MRSA (>50%) are reported in North and South America, Asia, and Malta. Intermediate rates (25–50%) are reported in China, Australia, Africa, and several European countries [e.g. Portugal (49%), Greece (40%), Italy (37%) and Romania (34%)]. Most European countries have low prevalence rates (e.g. Netherlands and Scandinavia).^{39–41}

III. The biofilm state

Implantable medical devices have revolutionized modern healthcare. Unfortunately, attachment to indwelling devices by surface-adhering bacteria increases patient morbidity and mortality. Biofilms formed by *Staphylococci* are the most common cause of biofilm-associated infections with *S. aureus* being among the most common cause of device related infections (DRI).^{42–44} All implanted medical devices are susceptible to colonization by *Staphylococci*. As a result, biofilm-associated infections have been associated with devices such as implanted catheters, prosthetic heart valves, cardiac pacemakers, contact lenses, cerebrospinal fluid shunts, joint replacements, and intravascular lines. To exacerbate the problem, infections associated with biofilms are particularly difficult to treat as bacteria within the matrix are more resistant to antimicrobial agents and the host immune response than planktonic bacteria. This increased resistance is attributable both to the protection afforded by the biofilm matrix as well as the unique phenotypic characteristics of bacteria within the matrix.




Fig. 3 Global prevalence of hospital-acquired MRSA.

The first stage of biofilm formation is the attachment of a bacterial cell to a living (biotic) or non-living (abiotic) surface (Fig. 4).⁴⁵ Following attachment, bacteria in the biofilm state progress through a growth and maturation phase.⁴⁶ At the molecular level, the biofilm matrix is composed of an extracellular polymeric substance (EPS) composed primarily of oligosaccharides, DNA, and proteins.⁴⁷ The primary oligosaccharide in *S. aureus* biofilm matrices is a polymer of *N*-acetyl- β -(1-6)-glucosamine (polysaccharide intercellular adhesin or PIA), while the accumulation-associated protein (Aap) is a common biofilm-associated protein. Teichoic acids are also common biofilm components. At the end of the biofilm cycle, cell clusters detach from the larger biofilm structure. Detachment is facilitated by expression of surfactant-like peptides, which are also critical to biofilm integrity and three-dimensional structure. Once detached, cell clusters can start new biofilm colonies on other surfaces.

S. aureus pathogenesis and biofilm development is controlled by cell-to-cell communication using a ubiquitous regulatory system called quorum sensing.^{48–52} During its growth and maturation phase, *S. aureus* produces an autoinducing peptide (AIP) that accumulates in the extracellular environment. Once AIP levels reach a specific concentration, the signal binds to a bacterial surface receptor and activates a regulatory cascade. The outcome is an increased expression of invasive factors such as toxins, hemolysins, proteases, and other tissue-degrading enzymes. Interestingly, these factors alter the metabolic status of the bacteria which subsequently changes their biofilm-forming capacity. Unfortunately, the relationship between environmental stress and pathogenesis remains poorly understood.

IV. Biofilm-mediated antimicrobial resistance

It has long been recognized that biofilms increase resistance to antimicrobial action from both external agents, such as antibiotics, and internal agents of the innate immune system, such as antimicrobial peptides (AMPs).⁵³ Broadly speaking, two mechanisms are responsible for biofilm-mediated resistance. The first is prevention of chemotherapeutics from reaching their target due to limited diffusion or repulsion caused by the biofilm matrix itself.^{2,8,54} The second mechanism involves alteration of the physiology of biofilm-dwelling bacteria compared to planktonic bacteria.




Fig. 4 The biofilm life cycle.

Cells within the biofilm, particularly those deep within the matrix, are generally thought to exist in a slow-growing state; these slow-growing cells are referred to as dormant or persister cells. Persister cells are a small fraction of exponentially growing cells, but are *ca.* 1% of bacteria in both the stationary phase and in biofilms. The decreased growth rate of persister cells can limit the efficacy of antibiotics, especially those that target active cell processes, without the need for genetic alteration.^{55–57} For example, this type of cell would be immune to β -lactams that target cell wall formation in actively dividing cells.^{28,29,54} The ability of dormant cells to survive numerous rounds of antibiotic treatment also makes them key contributors to the restoration of biofilm communities.⁵⁴

V. Strategies to combat MRSA biofilms

The development of strategies to prevent, remove, or disperse biofilms are as critical to treating staph infections as the development of new antibiotics.^{58–63} A frontier approach in the battle against *S. aureus* is to develop anti-biofilm strategies that can be combined with conventional antibiotics as a means to restore antibiotic efficacy to levels observed when treating planktonic bacteria. In this section, we will discuss several approaches used to eradicate MRSA biofilms. These strategies can be broken down broadly into two categories: prevention of biofilm formation (antibiotic chemotherapy, anti-adhesive coatings/surfaces) and elimination of established *S. aureus* biofilms.

A. Antibiotic therapy

The best method for treating a biofilm-related infection is by preventing initial infection altogether. Unfortunately, the facile evolution of antibiotic resistance by *S. aureus* poses a significant challenge to this approach. Biofilms compound this issue by significantly increasing antibiotic minimum inhibitory concentrations (MICs) compared to cells in the planktonic state.⁶⁴ For example, the MIC for vancomycin, the most commonly administered drug for *S. aureus* biofilm-associated infections, is 10-times higher for biofilm-bound cells than for planktonic, free-floating cells (planktonic cell MIC = *ca.* 2 $\mu\text{g ml}^{-1}$, biofilm bound cell MIC = *ca.* 20 $\mu\text{g ml}^{-1}$).⁶⁵

Despite growing resistance levels, there do exist antibiotics, such as daptomycin (5) that are effective at treating even VRSA biofilm-related infections (Fig. 5). Daptomycin, a cyclic lipopeptide molecule, is a novel antibiotic that disrupts the cytoplasmic membrane *via* rapid depolarization and interruption of DNA, RNA, and protein synthesis. Importantly, daptomycin is one of the most effective antibiotics at clearing *S. aureus* from an existing biofilm.⁶⁶ Moreover, because the mode of action for daptomycin does not require cells to be in a metabolically active state, it is a particularly useful agent in the fight against persister cells embedded deep within the biofilm matrix.




Fig. 5 Select antibiofilm small molecules.

B. Physical methods for biofilm removal

Second to preventing initial infection and, by extension, initial formation of a biofilm matrix, the next simplest method to treat an *S. aureus* biofilm-mediated infection is through surgical removal of the biofilm abscess.⁶⁷ Removal can occur through debridement of wounds or surgical implants. Irrigation and pulsed lavage are also strategies that are commonly employed. Unfortunately, techniques that apply purely physical tools have limited success. For example, pulse lavage irrigation is ineffective at eliminating *S. aureus* biofilms present on indwelling devices.⁶⁸

C. Attachment prevention

Attachment of bacteria to abiotic surfaces is mediated by a number of factors such as adhesion surface proteins, fimbriae or pili, and exopolysaccharides.^{69,70} Adhesion occurs most readily on surfaces that are coarse or hydrophobic. As hospitals are rich with these types of surfaces, hospitals are a major source of device-associated infections. In a similar vein, indwelling medical devices often feature coarse or hydrophobic surfaces and thus present another potential colonization surface. Due to the prevalence of device-related infections, there has been increased interest in developing anti-infective strategies to prevent colonization.^{71–74}

While adhesion to abiotic surfaces, such as metal and plastics, proceeds through nonspecific mechanisms, adherence to

biotic surfaces is dependent on surface proteins that are anchored to the cell wall peptidoglycan.^{75,76} Indeed, cell surface proteins, which are designed to recognize host surfaces, are critical for *S. aureus* adherence to host tissues as well as subsequent tissue colonization and ultimately the survival of MRSA infections. Surface proteins known to play important roles in biofilm formation include Bap, clumping factors (ClfB), FnBPs, SasC, SasG, and protein A. ClfB, FnBPs and protein A are widely distributed.^{77–81} To target these proteins, and thus disrupt attachment, the Clubb group used an array of small molecules to inhibit MRSA transpeptidase sortase A; MRSA transpeptidase sortase A is a protein that anchors surface proteins to the cell wall.^{82,83} In theory, cell surface proteins are a novel therapeutic target to disrupt adhesion or adherence and mitigate biofilm formation.

Whether dealing with biotic or abiotic surfaces, the frontier challenge in attachment prevention methods remains understanding how bacteria coordinate the expression of different effectors and how various surfaces, particularly cellular surfaces, react to these effectors. If this communication system can be deciphered, one can develop strategies to eradicate biofilms by blocking initial adherence of the microbe. In the proceeding sections, several coatings that prevent bacterial attachment to and growth on surfaces are described.

C1. Small molecules. Aryl rhodanines (6) are 5-membered ring heterocycles that are known to inhibit biofilm formation in several Gram-positive models, including *Staphylococcal* and *Enterococcal* species (Fig. 5).⁸⁴ Aryl rhodanines function by inhibiting attachment of bacterial cells through a mechanism that likely involves complexation of the rhodanines to one or more adhesins located on the microbial cell surface. Interestingly, aryl rhodanines are inactive against Gram-negative microbes. Importantly, while rhodanines possess anti-biofilm activity, they do not possess antimicrobial activity and are not cytotoxic against human cells. From a therapeutic perspective, rhodanines have the potential to be important tools in the battle against MRSA as their lack of antimicrobial activity reduces selective pressure. In other words, this class of small molecule is less likely to produce resistant strains or to induce high levels of biofilm production as a means to protect against a strong antimicrobial substance.

C2. Abiotic surface coating. Catheters coated with tetracyclines and ansamycins, both of which are bacteriostatic as opposed to bactericidal antibiotics, have been shown to decrease the frequency of MRSA central line-associated bloodstream infection (CLABSI) in ICUs.^{85,86} This result suggests that alteration of the surface properties of an indwelling device by coating the surface with bacteriostatic agents can prevent biofilm-associated infections.

A number of metals have also been used to coat abiotic surfaces, such as catheters, in an effort to prevent biofilm formation.⁸⁷ The most well-known example is silver in the form of elemental silver, silver ions, and/or silver nanoparticles.^{88–90} Silver is effective at preventing biofilm formation against both Gram-positive and Gram-negative microbes, including MRSA.

Interestingly, although silver coatings are frequently used, the mechanism of action behind silver-mediated biofilm production prevention remains unknown. However, changes to bacterial cell morphology have hinted at several mechanisms. For example, silver nanoparticles have been shown to attach to the bacterial membrane and penetrate the cell. After gaining entrance, the nanoparticles engage sulfide-containing proteins and DNA. This resultantly inhibits DNA replication and transcription. Thus, it is thought that silver prevents biofilm production by serving as an antimicrobial agent.

While silver-coating is common, there are cytotoxicity concerns with this method. Silver accelerates thrombin formation and platelet activation which subsequently places patients at higher risk for thrombosis. To avoid this issue, stainless steel and titanium have also been used to coat implant materials.^{91–93} Interestingly, a number of medical devices have also been coated with vancomycin to prevent MRSA adherence.

D. Treatment or dispersal of established biofilms

D1. Small molecules. *Cis*-2-Decenoic acid (C2DA, 7) is a medium-chain fatty acid produced by *Pseudomonas aeruginosa* that has been shown not only to possess the ability to disperse established MRSA biofilms but also to completely inhibit MRSA biofilm formation (Fig. 5).^{94,95} In addition to this lipid, it has been shown that D-amino acids disperse established biofilms in *S. aureus*. Incorporation of D-amino acids into the peptidoglycan layer results in the release of amyloid fibers, a component of the extracellular matrix that connects cells in the biofilm matrix.^{96–99} Kolodkin-Gal demonstrated that D-amino acids disperse *Bacillus subtilis* biofilms by affecting the function of these amyloid fibers.¹⁰⁰ Mechanistically, when noncanonical amino acids are incorporated into the peptidoglycan layer, they interfere with the normal anchoring that helps maintain biofilm architecture integrity. Moreover, D-amino acids compete with canonical amino acids for positions in the peptidoglycan layer which interferes with transpeptidation and transglycosylation. Importantly, this disruption of bacterial cell wall composition caused by D-amino acid incorporation interferes with biofilm formation (Fig. 6).

D2. Matrix degrading enzymes. Disruption of biofilm matrix structural integrity is an attractive approach to limit the protective effects the matrix affords cells enclosed within it. This method is the reason for the addition of exogenous




Fig. 6 General methods for biofilm dispersal.

enzymes, such as dispersion B or DNAase, to *S. aureus* biofilms.^{101–104} DNAase works by degrading the extracellular DNA in the biofilm matrix EPS, while dispersin B targets the polysaccharide EPS component. As biofilm matrices consist largely of extracellular DNA and polysaccharides, the actions of dispersin B and DNase serve to destabilize the matrix. It is important to note, however, that the use of exogenous enzymes like as dispersin B and DNase to disrupt *S. aureus* biofilm formation does have its shortcomings. For example, the susceptibility of *S. aureus* to dispersin B differs significantly among strains. Moreover, a number of clinically relevant MRSA strains produce biofilms that contain little polysaccharide which serves to limit the influence of dispersin B treatment on biofilm production.

D3. Plant-derived natural compounds. Natural products are critical to the discovery and development of new anti-infective agents against MRSA.^{59–62} For example, extracts from the broths of *Krameria*, *Aesculus hippocastanum*, and *Conopodium majus* each contains four compounds that have all been shown to inhibit *S. aureus* biofilm formation: chelerythrine (8), dihydroxybenzofuran (9), sanguinarine (10), and proanthocyanidin (11) (Fig. 5).¹⁰⁵ American cranberry extracts, which contain proanthocyanidins (PAC), have also been shown to inhibit *S. aureus* biofilm formation as well as *S. aureus* growth.^{106,107} Moreover, polyphenolic compounds found in plant tissues, such as tannic acid (12), are known to inhibit *S. aureus* biofilm formation (Fig. 5).^{108,109}

Tea-tree oil, an essential oil extracted from the leaves of *Melaleuca alternifolia*, eradicates biofilm production by *S. aureus*, including MRSA, by damaging the extracellular matrix.^{110,111} This damage initiates subsequent removal of the biofilm from biotic surfaces. Ellagic acid (13) derivatives from *Rubus ulmifolius* limit *S. aureus* biofilm production and also enhance the susceptibility of *S. aureus* to the antibiotics daptomycin, clindamycin, and oxacillin without contaminant cytotoxicity to mammalian cells (Fig. 5).^{112,113}

Although the agents discussed in the section are effective at combatting biofilms, their modes of action remain unclear.

Conclusion and future outlook

Rising MRSA infection rates pose a significant threat to human health. While increasing antibiotic resistance is a well-appreciated contributing factor, a lesser appreciated but equally important factor is the ability of *S. aureus* to form biofilms. Biofilms serve to protect *S. aureus* from host defenses and antibiotics alike and are consequently integral to *S. aureus* pathogenesis. Indeed, biofilm-dwelling bacteria are generally able to tolerate much higher antibiotic concentrations than their planktonic counterparts. The increased resistance of biofilm-associated bacteria against antimicrobial action is attributable to the physical barrier between bacteria and antimicrobial afforded by the biofilm matrix as well as the phenotypic shift bacteria embedded in the matrix undergo. As a result, biofilm-associated infections are notoriously difficult to eradicate.

Indicative of the benefit of biofilm production for *S. aureus* survival, most chronic MRSA infections leverage the biofilm state in their pathogenesis. This is especially true for those associated with indwelling medical devices. As most therapeutic strategies are only effective at treating planktonic cells or acute infections, there is an urgent need to develop new therapeutic strategies capable of targeting *S. aureus* in the biofilm state. Unfortunately, despite much effort, the development of useful biofilm inhibitors and/or dispersal agents for *Staphylococcal* biofilms is in its infancy. While many innovative approaches to eradicate *S. aureus* biofilms have been achieved over the past two decades such as small molecules that prevent biofilm formation, enzymes that weaken biofilm matrix structural integrity, and antibodies and vaccines that target specific biofilm life cycle stages, these approaches lack clinical validation.

One potential future source of antibiofilm compounds are cationic small molecules. Indeed, several recent studies have showcased the ability of positively-charged molecules to disrupt biofilm matrices and inhibit biofilm formation by a number of pathogens.^{114–119} However, the antibiofilm activity of this class of molecule is generally accompanied by antimicrobial activity. Although this may seem beneficial, the antimicrobial activity is likely to induce selective pressure and promote the evolution of resistant bacteria. Additionally, care must be taken with cationic molecules to limit cytotoxicity to mammalian cells. Given these concerns, identifying cationic small molecules with exclusive antibiofilm activity represents an exciting research avenue.

Another approach, one which our lab has begun to investigate, is to use host defense mechanisms as a source of molecular inspiration. We recently demonstrated that human milk oligosaccharides (HMOs), non-conjugated oligosaccharides abundant in human milk, modulate growth and biofilm production for several bacterial pathogens, including MRSA.¹²⁰ However, we have yet to identify the mechanism of action behind the antibiofilm activity observed. In a parallel study, we discovered that conversion of the ubiquitous HMO 2'-fucosyllactose (2'-FL) to an anomeric, amino-variant gave a compound with impressive antibiofilm activity against Group B Streptococcus.¹²¹ Once again, the mechanism behind this antibiofilm activity remains unknown. Thus, future studies are directed at elucidating a mechanism of action as well as investigating if this result translates to an *S. aureus* model.

In addition to these approaches, as previously mentioned, further elucidation of how bacteria coordinate the expression of various effectors and how surfaces react with these effectors will be paramount to the development of antibiofilm compounds. Indeed, a greater understanding of this communication system has the potential to identify unique bacterial targets that can be engaged to target biofilm production selectively without accompanying antimicrobial activity.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Financial support is provided by Vanderbilt University, the Vanderbilt Microbiome Initiative (VMI), the Vanderbilt Pre³ Initiative, a Deans Faculty Fellowship, Glycosyn, FrieslandCampina, and the National Science Foundation (CA-REER Award to SDT: CHE-1847804). K. M. C. is supported by the Vanderbilt Chemical Biology Interface (CBI) training program (T32 GM065086), the Vanderbilt Pre³ Initiative (travel grant), and the Mitchum E. Warren, Jr. Graduate Research Fellowship. Johnny M. Nguyen acknowledges the Gates Millennium Scholars (GMS) Program for a graduate research fellowship. Lawrence J. Berg acknowledges the Beckman Foundation for a Beckman Scholars Program Fellowship.

Notes and references

- 1 Y. Mo, I. Low, S. K. Tambyah and P. A. Tambyah, The socio-economic impact of multidrug-resistant nosocomial infections: a qualitative study, *J. Hosp. Infect.*, 2018, DOI: 10.1016/j.jhin.2018.08.013.
- 2 J. Y. Choi, Y. G. Kwak, H. Yoo, S. O. Lee, H. B. Kim and S. H. Han, *et al.*, Trends in the distribution and antimicrobial susceptibility of causative pathogens of device-associated infection in Korean intensive care units from 2006 to 2013: results from the Korean Nosocomial Infections Surveillance System (KONIS), *J. Hosp. Infect.*, 2016, **92**(4), 363–371.
- 3 N. Alai, Enhancing best practices in ophthalmology for prevention of nosocomial epidemic keratoconjunctivitis infections, *Curr. Med. Res. Opin.*, 2016, **32**(10), 1757–1758.
- 4 P. Lackner, C. Mueller, R. Beer, G. Broessner, M. Fischer and R. Helbok, *et al.*, Nosocomial Infections and Antimicrobial Treatment in Coiled Patients with Aneurysmal Subarachnoid Hemorrhage, *Curr. Drug Targets*, 2017, **18**(12), 1417–1423.
- 5 M. Sutcu, N. Salman, H. Akturk, N. Dalgic, O. Turel and C. Kuzdan, *et al.*, Epidemiologic and microbiologic evaluation of nosocomial infections associated with *Candida* spp in children: A multicenter study from Istanbul, Turkey, *Am. J. Infect. Control*, 2016, **44**(10), 1139–1143.
- 6 T. Heister, K. Kaier and M. Wolkewitz, Estimating the burden of nosocomial infections: Time dependency and cost clustering should be taken into account, *Am. J. Infect. Control*, 2017, **45**(1), 94–95.
- 7 P. P. Tsitsopoulos, E. Iosifidis, C. Antachopoulos, D. M. Anestis, E. Karantani and A. Karyoti, *et al.*, Nosocomial bloodstream infections in neurosurgery: a 10-year analysis in a center with high antimicrobial drug-resistance prevalence, *Acta Neurochir.*, 2016, **158**(9), 1647–1654.
- 8 P. W. Stone, D. Braccia and E. Larson, Systematic review of economic analyses of health care-associated infections, *Am. J. Infect. Control*, 2005, **33**(9), 501–509.
- 9 W. Zingg, S. Hopkins, A. Gayet-Ageron, A. Holmes, M. Sharland and C. Suetens, *et al.*, Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey, *Lancet Infect. Dis.*, 2017, **17**(4), 381–389.
- 10 N. Kariya, N. Sakon, J. Komano, K. Tomono and H. Iso, Current prevention and control of health care-associated infections in long-term care facilities for the elderly in Japan, *J. Infect. Chemother.*, 2018, **24**(5), 347–352.
- 11 S. S. Wong, C. H. Huang, C. C. Yang, Y. P. Hsieh, C. N. Kuo and Y. R. Chen, *et al.*, Reducing health care-associated infections by implementing separated environmental cleaning management measures by using disposable wipes of four colors, *Antimicrob. Resist. Infect. Control*, 2018, **7**, 34.
- 12 S. Bagheri Nejad, B. Allegranzi, S. B. Syed, B. Ellis and D. Pittet, Health-care-associated infection in Africa: a systematic review, *Bull. W. H. O.*, 2011, **89**(10), 757–765.
- 13 WHO, *Health care-associated infections FACT SHEET*.
- 14 J. L. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto and C. D. Martin, *et al.*, International study of the prevalence and outcomes of infection in intensive care units, *JAMA, J. Am. Med. Assoc.*, 2009, **302**(21), 2323–2329.
- 15 E. J. Choo, Community-Associated Methicillin-Resistant *Staphylococcus aureus* in Nosocomial Infections, *Infect. Chemother.*, 2017, **49**(2), 158–159.
- 16 R. Valaperta, M. R. Tejada, M. Frigerio, A. Moroni, E. Ciulla and S. Cioffi, *et al.*, *Staphylococcus aureus* nosocomial infections: the role of a rapid and low-cost characterization for the establishment of a surveillance system, *New Microbiol.*, 2010, **33**(3), 223–232.
- 17 C. A. Alvarez, N. Yomayusa, A. L. Leal, J. Moreno, S. Mendez-Alvarez and M. Ibanez, *et al.*, Nosocomial infections caused by community-associated methicillin-resistant *Staphylococcus aureus* in Colombia, *Am. J. Infect. Control*, 2010, **38**(4), 315–318.
- 18 S. Y. Tong, J. S. Davis, E. Eichenberger, T. L. Holland and V. G. Fowler Jr., *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management, *Clin. Microbiol. Rev.*, 2015, **28**(3), 603–661.
- 19 D. N. Frank, L. M. Feazel, M. T. Bessesen, C. S. Price, E. N. Janoff and N. R. Pace, The human nasal microbiota and *Staphylococcus aureus* carriage, *PLoS One*, 2010, **5**(5), e10598.
- 20 J. U. Sollid, A. S. Furberg, A. M. Hanssen and M. Johannessen, *Staphylococcus aureus*: determinants of human carriage, *Infect., Genet. Evol.*, 2014, **21**, 531–541.
- 21 S. D. Kobayashi, N. Malachowa and F. R. DeLeo, Pathogenesis of *Staphylococcus aureus* abscesses, *Am. J. Pathol.*, 2015, **185**(6), 1518–1527.
- 22 C. B. Creech, D. N. Al-Zubeidi and S. A. Fritz, Prevention of Recurrent Staphylococcal Skin Infections, *Infect. Dis. Clin. North Am.*, 2015, **29**(3), 429–464.
- 23 N. Oztoprak, M. A. Cevik, E. Akinci, M. Korkmaz, A. Erbay and S. S. Eren, *et al.*, Risk factors for ICU-acquired methicillin-resistant *Staphylococcus aureus* infections, *Am. J. Infect. Control*, 2006, **34**(1), 1–5.
- 24 K. J. Hardy, P. M. Hawkey, F. Gao and B. A. Oppenheim, Methicillin resistant *Staphylococcus aureus* in the critically ill, *Br. J. Anaesth.*, 2004, **92**(1), 121–130.

- 25 M. M. Gallardo-Garcia, G. Sanchez-Espin, R. Ivanova-Georgieva, J. Ruiz-Morales, I. Rodriguez-Bailon and V. Vinuela Gonzalez, *et al.*, Relationship between pathogenic, clinical, and virulence factors of Staphylococcus aureus in infective endocarditis versus uncomplicated bacteremia: a case-control study, *Eur. J. Clin. Microbiol. Infect. Dis.*, 2016, 35(5), 821–828.
- 26 K. A. Lacey, J. A. Geoghegan and R. M. McLoughlin, The Role of Staphylococcus aureus Virulence Factors in Skin Infection and Their Potential as Vaccine Antigens, *Pathogens*, 2016, 5(1), 22.
- 27 S. J. Peacock and G. K. Paterson, Mechanisms of Methicillin Resistance in Staphylococcus aureus, *Annu. Rev. Biochem.*, 2015, 84, 577–601.
- 28 J. W. Costerton, P. S. Stewart and E. P. Greenberg, Bacterial biofilms: a common cause of persistent infections, *Science*, 1999, 284(5418), 1318–1322.
- 29 D. Davies, Understanding biofilm resistance to antibacterial agents, *Nat. Rev. Drug Discovery*, 2003, 2(2), 114–122.
- 30 M. C. Haug, S. A. Tanner, C. Lacroix, M. J. Stevens and L. Meile, Monitoring horizontal antibiotic resistance gene transfer in a colonic fermentation model, *FEMS Microbiol. Ecol.*, 2011, 78(2), 210–219.
- 31 C. P. Andam, G. P. Fournier and J. P. Gogarten, Multilevel populations and the evolution of antibiotic resistance through horizontal gene transfer, *FEMS Microbiol. Rev.*, 2011, 35(5), 756–767.
- 32 A. O. Summers, Genetic linkage and horizontal gene transfer, the roots of the antibiotic multi-resistance problem, *Anim. Biotechnol.*, 2006, 17(2), 125–135.
- 33 H. F. Chambers and F. R. Deleo, Waves of resistance: Staphylococcus aureus in the antibiotic era, *Nat. Rev. Microbiol.*, 2009, 7(9), 629–641.
- 34 C. W. Hicks, J. A. Blatnik, D. M. Krpata, Y. W. Novitsky and M. J. Rosen, History of methicillin-resistant Staphylococcus aureus (MRSA) surgical site infection may not be a contraindication to ventral hernia repair with synthetic mesh: a preliminary report, *Hernia*, 2014, 18(1), 65–70.
- 35 F. D. Lowy, Antimicrobial resistance: the example of Staphylococcus aureus, *J. Clin. Invest.*, 2003, 111(9), 1265–1273.
- 36 P. D. Stapleton and P. W. Taylor, Methicillin resistance in Staphylococcus aureus, *Sci. Prog.*, 2002, 85, 57–72.
- 37 W. A. McGuinness, N. Malachowa and F. R. DeLeo, Vancomycin Resistance in Staphylococcus aureus, *Yale J. Biol. Med.*, 2017, 90(2), 269–281.
- 38 A. Okano, N. A. Isley and D. L. Boger, Total Syntheses of Vancomycin-Related Glycopeptide Antibiotics and Key Analogues, *Chem. Rev.*, 2017, 117(18), 11952–11993.
- 39 A. Hassoun, P. K. Linden and B. Friedman, Incidence, prevalence, and management of MRSA bacteremia across patient populations—a review of recent developments in MRSA management and treatment, *Crit. Care*, 2017, 21(1), 211.
- 40 G. Igrejas, S. Correia, V. Silva, M. Hebraud, M. Canica and C. Torres, *et al.*, Planning a One Health Case Study to Evaluate Methicillin Resistant Staphylococcus aureus and Its Economic Burden in Portugal, *Front. Microbiol.*, 2018, 9, 2964.
- 41 H. Uematsu, K. Yamashita, S. Kunisawa, K. Fushimi and Y. Imanaka, The economic burden of methicillin-resistant Staphylococcus aureus in community-onset pneumonia inpatients, *Am. J. Infect. Control*, 2016, 44(12), 1628–1633.
- 42 D. C. Vinh and J. M. Embil, Device-related infections: a review, *J. Long-Term Eff. Med. Implants*, 2005, 15(5), 467–488.
- 43 L. W. Duran, Preventing medical device related infections, *Med. Device Technol.*, 2000, 11(6), 14–17.
- 44 T. L. Lin, F. M. Lu, S. Conroy, M. S. Sheu, S. H. Su and L. Tang, Antimicrobial coatings: a remedy for medical device-related infections, *Med. Device Technol.*, 2001, 12(8), 26–30.
- 45 B. Schachter, Slimy business—the biotechnology of biofilms, *Nat. Biotechnol.*, 2003, 21(4), 361–365.
- 46 R. Gregor, S. David and M. M. Meijler, Chemical strategies to unravel bacterial-eukaryotic signaling, *Chem. Soc. Rev.*, 2018, 47(5), 1761–1772.
- 47 H.-C. Flemming and J. Wingender, The biofilm matrix, *Nat. Rev. Microbiol.*, 2010, 8(9), 623–633.
- 48 M. A. Welsh and H. E. Blackwell, Chemical probes of quorum sensing: from compound development to biological discovery, *FEMS Microbiol. Rev.*, 2016, 40(5), 774–794.
- 49 T. Praneenararat, A. G. Palmer and H. E. Blackwell, Chemical methods to interrogate bacterial quorum sensing pathways, *Org. Biomol. Chem.*, 2012, 10(41), 8189–8199.
- 50 J. M. Yarwood and P. M. Schlievert, Quorum sensing in Staphylococcus infections, *J. Clin. Invest.*, 2003, 112(11), 1620–1625.
- 51 J. M. Yarwood, D. J. Bartels, E. M. Volper and E. P. Greenberg, Quorum sensing in Staphylococcus aureus biofilms, *J. Bacteriol.*, 2004, 186(6), 1838–1850.
- 52 K. F. Kong, C. Vuong and M. Otto, Staphylococcus quorum sensing in biofilm formation and infection, *Int. J. Med. Microbiol.*, 2006, 296(2–3), 133–139.
- 53 P. G. Bowler, Antibiotic resistance and biofilm tolerance: a combined threat in the treatment of chronic infections, *J. Wound Care*, 2018, 27(5), 273–277.
- 54 L. Hall-Stoodley, J. W. Costerton and P. Stoodley, Bacterial biofilms: from the natural environment to infectious diseases, *Nat. Rev. Microbiol.*, 2004, 2(2), 95–108.
- 55 S. Miyaue, E. Suzuki, Y. Komiyama, Y. Kondo, M. Morikawa and S. Maeda, Bacterial Memory of Persisters: Bacterial Persister Cells Can Retain Their Phenotype for Days or Weeks After Withdrawal From Colony-Biofilm Culture, *Front. Microbiol.*, 2018, 9, 1396.
- 56 T. K. Wood, Strategies for combating persister cell and biofilm infections, *Microb. Biotechnol.*, 2017, 10(5), 1054–1056.
- 57 B. P. Conlon, S. E. Rowe and K. Lewis, Persister cells in biofilm associated infections, *Adv. Exp. Med. Biol.*, 2015, 831, 1–9.
- 58 R. J. Melander and C. Melander, Innovative strategies for combating biofilm-based infections, *Adv. Exp. Med. Biol.*, 2015, 831, 69–91.

- 59 M. S. Blackledge, R. J. Worthington and C. Melander, Biologically inspired strategies for combating bacterial biofilms, *Curr. Opin. Pharmacol.*, 2013, 13(5), 699–706.
- 60 R. J. Worthington, J. J. Richards and C. Melander, Small molecule control of bacterial biofilms, *Org. Biomol. Chem.*, 2012, 10(37), 7457–7474.
- 61 S. D. Stowe, J. J. Richards, A. T. Tucker, R. Thompson, C. Melander and J. Cavanagh, Anti-biofilm compounds derived from marine sponges, *Mar. Drugs*, 2011, 9(10), 2010–2035.
- 62 J. J. Richards and C. Melander, Controlling bacterial biofilms, *ChemBioChem*, 2009, 10(14), 2287–2294.
- 63 J. J. Richards, R. W. Huigens Iii, T. E. Ballard, A. Basso, J. Cavanagh and C. Melander, Inhibition and dispersion of proteobacterial biofilms, *Chem. Commun.*, 2008(14), 1698–1700.
- 64 R. J. Melander and C. Melander, The Challenge of Overcoming Antibiotic Resistance: An Adjuvant Approach?, *ACS Infect. Dis.*, 2017, 3(8), 559–563.
- 65 A. H. Salem, W. F. Elkhatib and A. M. Noreddin, Pharmacodynamic assessment of vancomycin-rifampicin combination against methicillin resistant *Staphylococcus aureus* biofilm: a parametric response surface analysis, *J. Pharm. Pharmacol.*, 2011, 63(1), 73–79.
- 66 K. Smith, A. Perez, G. Ramage, C. G. Gemmell and S. Lang, Comparison of biofilm-associated cell survival following in vitro exposure of methicillin-resistant *Staphylococcus aureus* biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin, *Int. J. Antimicrob. Agents*, 2009, 33(4), 374–378.
- 67 M. Bhattacharya, D. J. Wozniak, P. Stoodley and L. Hall-Stoodley, Prevention and treatment of *Staphylococcus aureus* biofilms, *Expert Rev. Anti-infect. Ther.*, 2015, 13(12), 1499–1516.
- 68 K. L. Urish, P. W. DeMuth, D. W. Craft, H. Haider and C. M. Davis 3rd, Pulse lavage is inadequate at removal of biofilm from the surface of total knee arthroplasty materials, *J. Arthroplasty*, 2014, 29(6), 1128–1132.
- 69 M. P. Arena, V. Capozzi, G. Spano and D. Fiocco, The potential of lactic acid bacteria to colonize biotic and abiotic surfaces and the investigation of their interactions and mechanisms, *Appl. Microbiol. Biotechnol.*, 2017, 101(7), 2641–2657.
- 70 C. Berne, A. Ducret, G. G. Hardy and Y. V. Brun, Adhesins Involved in Attachment to Abiotic Surfaces by Gram-Negative Bacteria, *Microbiol. Spectrum*, 2015, 3(4), DOI: 10.1128/microbiolspec.MB-0018-2015.
- 71 W. Zimmerli and P. Sendi, The Role of Rifampin against Staphylococcal Biofilm Infections in Vitro, in Animal Models, and in Orthopedic Device-Related Infections, *Antimicrob. Agents Chemother.*, 2018, DOI: 10.1128/AAC.01746-18.
- 72 J. Seidelman and S. S. Lewis, Neurosurgical Device-Related Infections, *Infect. Dis. Clin. North Am.*, 2018, 32(4), 861–876.
- 73 M. T. Buhmann, P. Stiefel, K. Maniura-Weber and Q. Ren, In Vitro Biofilm Models for Device-Related Infections, *Trends Biotechnol.*, 2016, 34(12), 945–948.
- 74 M. Morgenstern, C. Erichsen, C. von Ruden, W. J. Metsemakers, S. L. Kates and T. F. Moriarty, *et al.*, Staphylococcal orthopaedic device-related infections in older patients, *Injury*, 2016, 47(7), 1427–1434.
- 75 A. Merghni, M. Ben Nejma, I. Dallel, S. Tobji, A. Ben Amor and S. Janel, *et al.*, High potential of adhesion to biotic and abiotic surfaces by opportunistic *Staphylococcus aureus* strains isolated from orthodontic appliances, *Microb. Pathog.*, 2016, 91, 61–67.
- 76 C. Beloin, S. Da Re and J. M. Ghigo, Colonization of Abiotic Surfaces, *EcoSal Plus*, 2005, 1(2), DOI: 10.1128/ecosalplus.8.3.1.3.
- 77 S. J. Kim, J. Chang, B. Rimal, H. Yang and J. Schaefer, Surface proteins and the formation of biofilms by *Staphylococcus aureus*, *Biochim. Biophys. Acta, Biomembr.*, 2018, 1860(3), 749–756.
- 78 J. A. Geoghegan and T. J. Foster, Cell Wall-Anchored Surface Proteins of *Staphylococcus aureus*: Many Proteins, Multiple Functions, *Curr. Top. Microbiol. Immunol.*, 2017, 409, 95–120.
- 79 L. Foulston, A. K. Elsholz, A. S. DeFrancesco and R. Losick, The extracellular matrix of *Staphylococcus aureus* biofilms comprises cytoplasmic proteins that associate with the cell surface in response to decreasing pH, *mBio*, 2014, 5(5), e01667–14, DOI: 10.1128/mBio.01667-14.
- 80 J. Kwiecinski, T. Jin and E. Josefsson, Surface proteins of *Staphylococcus aureus* play an important role in experimental skin infection, *APMIS*, 2014, 122(12), 1240–1250.
- 81 T. J. Foster, J. A. Geoghegan, V. K. Ganesh and M. Hook, Adhesion, invasion and evasion: the many functions of the surface proteins of *Staphylococcus aureus*, *Nat. Rev. Microbiol.*, 2014, 12(1), 49–62.
- 82 A. H. Chan, J. Wereszczynski, B. R. Amer, S. W. Yi, M. E. Jung and J. A. McCammon, *et al.*, Discovery of *Staphylococcus aureus* sortase A inhibitors using virtual screening and the relaxed complex scheme, *Chem. Biol. Drug Des.*, 2013, 82(4), 418–428.
- 83 N. Suree, S. W. Yi, W. Thieu, M. Marohn, R. Damoiseaux and A. Chan, *et al.*, Discovery and structure-activity relationship analysis of *Staphylococcus aureus* sortase A inhibitors, *Bioorg. Med. Chem.*, 2009, 17(20), 7174–7185.
- 84 T. J. Opperman, S. M. Kwasny, J. D. Williams, A. R. Khan, N. P. Peet and D. T. Moir, *et al.*, Aryl rhodanines specifically inhibit staphylococcal and enterococcal biofilm formation, *Antimicrob. Agents Chemother.*, 2009, 53(10), 4357–4367.
- 85 I. R. Turnbull, S. A. Buckman, C. B. Horn, G. V. Bochicchio and J. E. Mazuski, Antibiotic-Impregnated Central Venous Catheters Do Not Change Antibiotic Resistance Patterns, *Surg. Infect.: Sel. Antibiot. Ther.*, 2018, 19(1), 40–47.
- 86 K. Harron, Q. Mok, D. Hughes, B. Muller-Pebody, R. Parslow and P. Ramnarayan, *et al.*, Generalisability and Cost-Impact of Antibiotic-Impregnated Central Venous Catheters for Reducing Risk of Bloodstream Infection in Paediatric Intensive Care Units in England, *PLoS One*, 2016, 11(3), e0151348.
- 87 D. Kowalczyk, G. Ginalska, T. Piersiak and M. Miazgarka, Prevention of biofilm formation on urinary

- catheters: comparison of the sparfloxacin-treated long-term antimicrobial catheters with silver-coated ones, *J. Biomed. Mater. Res., Part B*, 2012, **100**(7), 1874–1882.
- 88 X. Wang, J. Wu, P. Li, L. Wang, J. Zhou and G. Zhang, *et al.*, Microenvironment-Responsive Magnetic Nanocomposites Based on Silver Nanoparticles/Gentamicin for Enhanced Biofilm Disruption by Magnetic Field, *ACS Appl. Mater. Interfaces*, 2018, DOI: 10.1021/acsami.8b10972.
- 89 A. Pompilio, C. Geminiani, D. Bosco, R. Rana, A. Aceto and T. Bucciarelli, *et al.*, Electrochemically Synthesized Silver Nanoparticles Are Active Against Planktonic and Biofilm Cells of *Pseudomonas aeruginosa* and Other Cystic Fibrosis-Associated Bacterial Pathogens, *Front. Microbiol.*, 2018, **9**, 1349.
- 90 H. N. Wilkinson, S. Iveson, P. Catherall and M. J. Hardman, A Novel Silver Bioactive Glass Elicits Antimicrobial Efficacy Against *Pseudomonas aeruginosa* and *Staphylococcus aureus* in an ex Vivo Skin Wound Biofilm Model, *Front. Microbiol.*, 2018, **9**, 1450.
- 91 H. B. Dias, M. I. B. Bernardi, T. M. Bauab, A. C. Hernandez and A. N. de Souza Rastelli, Titanium dioxide and modified titanium dioxide by silver nanoparticles as an anti biofilm filler content for composite resins, *Dent. Mater.*, 2019, **35**(2), e36–e46.
- 92 M. K. Akens, C. Chien, R. N. Katchky, H. J. Kreder, J. Finkelstein and C. M. Whyne, The impact of thermal cycling on *Staphylococcus aureus* biofilm growth on stainless steel and titanium orthopaedic plates, *BMC Musculoskeletal Disord.*, 2018, **19**(1), 260.
- 93 M. Clauss, S. Graf, S. Gersbach, B. Hintermann, T. Ilchmann and M. Knupp, Material and biofilm load of K wires in toe surgery: titanium versus stainless steel, *Clin. Orthop. Relat. Res.*, 2013, **471**(7), 2312–2317.
- 94 D. T. Amari, C. N. Marques and D. G. Davies, The putative enoyl-coenzyme A hydratase DspI is required for production of the *Pseudomonas aeruginosa* biofilm dispersion autoinducer cis-2-decenoic acid, *J. Bacteriol.*, 2013, **195**(20), 4600–4610.
- 95 J. A. Jennings, H. S. Courtney and W. O. Haggard, Cis-2-decenoic acid inhibits *S. aureus* growth and biofilm in vitro: a pilot study, *Clin. Orthop. Relat. Res.*, 2012, **470**(10), 2663–2670.
- 96 E. C. Abenojar, S. Wickramasinghe, M. Ju, S. Uppaluri, A. Klika and J. George, *et al.*, Magnetic Glycol Chitin-Based Hydrogel Nanocomposite for Combined Thermal and d-Amino-Acid-Assisted Biofilm Disruption, *ACS Infect. Dis.*, 2018, **4**(8), 1246–1256.
- 97 R. Jia, Y. Li, H. H. Al-Mahamedh and T. Gu, Enhanced Biocide Treatments with D-amino Acid Mixtures against a Biofilm Consortium from a Water Cooling Tower, *Front. Microbiol.*, 2017, **8**, 1538.
- 98 A. J. Harmata, Y. Ma, C. J. Sanchez, K. J. Zienkiewicz, F. Elefteriou and J. C. Wenke, *et al.*, D-amino acid inhibits biofilm but not new bone formation in an ovine model, *Clin. Orthop. Relat. Res.*, 2015, **473**(12), 3951–3961.
- 99 D. Ausbacher, A. Fallarero, J. Kujala, A. Maattanen, J. Peltonen and M. B. Strom, *et al.*, *Staphylococcus aureus* biofilm susceptibility to small and potent beta(2,2)-amino acid derivatives, *Biofouling*, 2014, **30**(1), 81–93.
- 100 I. Kolodkin-Gal, D. Romero, S. Cao, J. Clardy, R. Kolter and R. Losick, D-amino acids trigger biofilm disassembly, *Science*, 2010, **328**(5978), 627–629.
- 101 R. M. Reddinger, N. R. Luke-Marshall, S. L. Sauberan, A. P. Hakansson and A. A. Campagnari, *Streptococcus pneumoniae* Modulates *Staphylococcus aureus* Biofilm Dispersion and the Transition from Colonization to Invasive Disease, *mBio*, 2018, **9**(1), DOI: 10.1128/mBio.02089-17.
- 102 R. M. Reddinger, N. R. Luke-Marshall, A. P. Hakansson and A. A. Campagnari, Host Physiologic Changes Induced by Influenza A Virus Lead to *Staphylococcus aureus* Biofilm Dispersion and Transition from Asymptomatic Colonization to Invasive Disease, *mBio*, 2016, **7**(4), DOI: 10.1128/mBio.01235-16.
- 103 C. Solano, M. Echeverz and I. Lasa, Biofilm dispersion and quorum sensing, *Curr. Opin. Microbiol.*, 2014, **18**, 96–104.
- 104 S. A. Rogers, M. Krayner, J. S. Lindsey and C. Melander, Tandem dispersion and killing of bacteria from a biofilm, *Org. Biomol. Chem.*, 2009, **7**(3), 603–606.
- 105 P. Y. Chung and Y. S. Toh, Anti-biofilm agents: recent breakthrough against multi-drug resistant *Staphylococcus aureus*, *Pathog. Dis.*, 2014, **70**(3), 231–239.
- 106 R. K. Ulrey, S. M. Barksdale, W. Zhou and M. L. van Hoek, Cranberry proanthocyanidins have anti-biofilm properties against *Pseudomonas aeruginosa*, *BMC Complementary Altern. Med.*, 2014, **14**, 499.
- 107 M. Feldman and D. Grenier, Cranberry proanthocyanidins act in synergy with licochalcone A to reduce *Porphyromonas gingivalis* growth and virulence properties, and to suppress cytokine secretion by macrophages, *J. Appl. Microbiol.*, 2012, **113**(2), 438–447.
- 108 G. Dong, H. Liu, X. Yu, X. Zhang, H. Lu and T. Zhou, *et al.*, Antimicrobial and anti-biofilm activity of tannic acid against *Staphylococcus aureus*, *Nat. Prod. Res.*, 2018, **32**(18), 2225–2228.
- 109 J. H. Lee, J. H. Park, H. S. Cho, S. W. Joo, M. H. Cho and J. Lee, Anti-biofilm activities of quercetin and tannic acid against *Staphylococcus aureus*, *Biofouling*, 2013, **29**(5), 491–499.
- 110 J. Kwiecinski, S. Eick and K. Wojeik, Effects of tea tree (*Melaleuca alternifolia*) oil on *Staphylococcus aureus* in biofilms and stationary growth phase, *Int. J. Antimicrob. Agents*, 2009, **33**(4), 343–347.
- 111 A. Raman, U. Weir and S. F. Bloomfield, Antimicrobial effects of tea-tree oil and its major components on *Staphylococcus aureus*, *Staph. epidermidis* and *Propionibacterium acnes*, *Lett. Appl. Microbiol.*, 1995, **21**(4), 242–245.
- 112 C. Sivasankar, S. Maruthupandian, K. Balamurugan, P. B. James, V. Krishnan and S. K. Pandian, A combination of ellagic acid and tetracycline inhibits biofilm formation and the associated virulence of *Propionibacterium acnes* in vitro and in vivo, *Biofouling*, 2016, **32**(4), 397–410.
- 113 C. L. Quave, M. Estevez-Carmona, C. M. Compadre, G. Hobby, H. Hendrickson and K. E. Beenken, *et al.*, Ellagic

- acid derivatives from *Rubus ulmifolius* inhibit *Staphylococcus aureus* biofilm formation and improve response to antibiotics, *PLoS One*, 2012, 7(1), e28737.
- 114 J. Hoque, M. M. Konai, S. S. Sequeira, S. Samaddar and J. Haldar, Antibacterial and Antibiofilm Activity of Cationic Small Molecules with Spatial Positioning of Hydrophobicity: An in Vitro and in Vivo Evaluation, *J. Med. Chem.*, 2016, 59(23), 10750–10762.
- 115 A. M. Carmona-Ribeiro and L. D. de Melo Carrasco, Cationic antimicrobial polymers and their assemblies, *Int. J. Mol. Sci.*, 2013, 14(5), 9906–9946.
- 116 J. Hoque, P. Akkapeddi, V. Yarlagadda, D. S. Uppu, P. Kumar and J. Haldar, Cleavable cationic antibacterial amphiphiles: synthesis, mechanism of action, and cytotoxicities, *Langmuir*, 2012, 28(33), 12225–12234.
- 117 A. Algburi, Y. Zhang, R. Weeks, N. Comito, S. Zehm and J. Pinto, *et al.*, Gemini Cationic Amphiphiles Control Biofilm Formation by Bacterial Vaginosis Pathogens, *Antimicrob. Agents Chemother.*, 2017, 61(12), DOI: 10.1128/AAC.00650-17.
- 118 C. de la Fuente-Nunez, V. Korolik, M. Bains, U. Nguyen, E. B. Breidenstein and S. Horsman, *et al.*, Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide, *Antimicrob. Agents Chemother.*, 2012, 56(5), 2696–2704.
- 119 G. Donelli, I. Francolini, A. Piozzi, R. Di Rosa and W. Marconi, New polymer-antibiotic systems to inhibit bacterial biofilm formation: a suitable approach to prevent central venous catheter-associated infections, *Aust. J. Chem.*, 2002, 14(5), 501–507.
- 120 D. L. Ackerman, K. M. Craft, R. S. Doster, J. H. Weitkamp, D. M. Aronoff and J. A. Gaddy, *et al.*, Antimicrobial and Antibiofilm Activity of Human Milk Oligosaccharides against *Streptococcus agalactiae*, *Staphylococcus aureus*, and *Acinetobacter baumannii*, *ACS Infect. Dis.*, 2018, 4(3), 315–324.
- 121 K. M. Craft and S. D. Townsend, 1-Amino-2'-fucosyllactose inhibits biofilm formation by *Streptococcus agalactiae*, *J. Antibiot.*, 2019, DOI: 10.1038/s41429-019-0151-6.